| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $969,668 ) |
| | 2024 | 2024 | ASTRAEA THERAPEUTICS LLC | 320 LOGUE AVE STE 142 | MOUNTAIN VIEW | CA | 94043-4040 | SANTA CLARA | USA | UH3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 001 | 5 | NIH | 7/18/2024 | $869,673 |
| | 2024 | 2024 | ASTRAEA THERAPEUTICS LLC | 320 LOGUE AVE STE 142 | MOUNTAIN VIEW | CA | 94043-4040 | SANTA CLARA | USA | UH3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 001 | 5 | NIH | 7/18/2024 | -$869,673 |
| | 2024 | 2024 | ASTRAEA THERAPEUTICS LLC | 320 LOGUE AVE STE 142 | MOUNTAIN VIEW | CA | 94043-4040 | SANTA CLARA | USA | UH3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 000 | 5 | NIH | 6/26/2024 | $869,673 |
| | 2024 | 2024 | ASTRAEA THERAPEUTICS LLC | 320 LOGUE AVE STE 142 | MOUNTAIN VIEW | CA | 94043-4040 | SANTA CLARA | USA | U01DA054882 | First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence | 000 | 3 | NIH | 4/12/2024 | $99,995 |
| | 2024 | 2023 | ASTRAEA THERAPEUTICS LLC | 320 LOGUE AVE STE 142 | MOUNTAIN VIEW | CA | 94043-4040 | SANTA CLARA | USA | U01DA054882 | First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence | 001 | 3 | NIH | 5/10/2024 | $0 |
| | 2024 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA047791 | DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE | 000 | 3 | NIH | 11/21/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,582,315 ) |
| | 2023 | 2023 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | UH3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 001 | 4 | NIH | 8/18/2023 | $2,183,507 |
| | 2023 | 2023 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA054882 | First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence | 000 | 3 | NIH | 4/28/2023 | $1,398,808 |
| | 2023 | 2022 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | UH3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 000 | 3 | NIH | 7/24/2023 | $0 |
| | 2023 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U18DA052559 | VALIDATING THE NOCICEPTIN RECEPTOR FOR TREATING CRAVING AND WITHDRAWAL-ASSOCIATED AFFECT IN COCAINE ADDICTION PHARMACOTHERAPY | 000 | 1 | NIH | 8/9/2023 | $0 |
| | 2023 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA047791 | DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE | 000 | 3 | NIH | 6/20/2023 | $0 |
| | 2023 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | UG3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 000 | 2 | NIH | 5/15/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $3,127,534 ) |
| | 2022 | 2022 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | UH3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 000 | 3 | NIH | 8/9/2022 | $1,020,256 |
| | 2022 | 2022 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA054882 | First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence | 003 | 2 | NIH | 5/10/2022 | $2,107,278 |
| | 2022 | 2021 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA054882 | First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence | 001 | 1 | NIH | 5/4/2022 | $0 |
| | 2022 | 2021 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA054882 | First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence | 002 | 1 | NIH | 5/9/2022 | $0 |
| | 2022 | 2021 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA054882 | First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence | 000 | 1 | NIH | 11/12/2021 | $0 |
| | 2022 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U18DA052559 | VALIDATING THE NOCICEPTIN RECEPTOR FOR TREATING CRAVING AND WITHDRAWAL-ASSOCIATED AFFECT IN COCAINE ADDICTION PHARMACOTHERAPY | 000 | 1 | NIH | 4/6/2022 | $0 |
| | 2022 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | UG3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 000 | 2 | NIH | 12/15/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,007,282 ) |
| | 2021 | 2021 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA054882 | First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence | 000 | 1 | NIH | 7/16/2021 | $2,007,282 |
| | 2021 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U18DA052559 | VALIDATING THE NOCICEPTIN RECEPTOR FOR TREATING CRAVING AND WITHDRAWAL-ASSOCIATED AFFECT IN COCAINE ADDICTION PHARMACOTHERAPY | 000 | 1 | NIH | 10/22/2020 | $0 |
| | 2021 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | UG3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 000 | 2 | NIH | 12/18/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,334,279 ) |
| | 2020 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U18DA052559 | VALIDATING THE NOCICEPTIN RECEPTOR FOR TREATING CRAVING AND WITHDRAWAL-ASSOCIATED AFFECT IN COCAINE ADDICTION PHARMACOTHERAPY | 000 | 1 | NIH | 9/15/2020 | $229,620 |
| | 2020 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | UG3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 001 | 2 | NIH | 2/11/2020 | $145,809 |
| | 2020 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | UG3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 002 | 2 | NIH | 9/10/2020 | -$1,458,094 |
| | 2020 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | UG3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 002 | 2 | NIH | 9/10/2020 | $1,458,094 |
| | 2020 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA047791 | DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE | 001 | 3 | NIH | 7/24/2020 | $646,565 |
| | 2020 | 2020 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | UG3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 000 | 2 | NIH | 12/19/2019 | $1,312,285 |
| | 2020 | 2019 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA047791 | DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE | 000 | 2 | NIH | 7/23/2020 | $0 |
| | 2020 | 2017 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | R44DA042465 | A NOVEL APPROACH FOR PAIN TREATMENT WITHOUT OPIOID LIABILITIES | 000 | 3 | NIH | 12/21/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $3,616,930 ) |
| | 2019 | 2019 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA047791 | DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE | 001 | 2 | NIH | 7/30/2019 | $2,158,836 |
| | 2019 | 2019 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | UG3DA048371 | Development of Next-generation Pharmacotherapy for Opioid Use Disorders | 000 | 1 | NIH | 12/26/2018 | $1,458,094 |
| | 2019 | 2018 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA047791 | DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE | 000 | 1 | NIH | 10/23/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,141,152 ) |
| | 2018 | 2018 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | U01DA047791 | DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE | 000 | 1 | NIH | 9/19/2018 | $1,141,152 |
| | 2018 | 2015 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | R44DA033744 | PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES | 000 | 3 | NIH | 8/28/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $736,013 ) |
| | 2017 | 2017 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | R44DA042465 | A NOVEL APPROACH FOR PAIN TREATMENT WITHOUT OPIOID LIABILITIES | 000 | 3 | NIH | 5/8/2017 | $736,013 |
| | 2017 | 2016 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | R44DA033744 | PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES | 001 | 3 | NIH | 5/4/2017 | $0 |
| | 2017 | 2015 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | R44DA033744 | PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES | 000 | 3 | NIH | 5/4/2017 | $0 |
| | 2017 | 2014 | ASTRAEA THERAPEUTICS LLC | 20170 SEA GULL WAY | SARATOGA | CA | 95070-3228 | SANTA CLARA | USA | R01DA027811 | Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy | 000 | 6 | NIH | 8/15/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $765,015 ) (Continued on the next page) |
| | 2016 | 2016 | ASTRAEA THERAPEUTICS LLC | 320 LOGUE AVE | MOUNTAIN VIEW | CA | 94043 | SANTA CLARA | USA | R44DA033744 | PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES | 000 | 3 | NIH | 5/12/2016 | $5,000 |
| | 2016 | 2016 | ASTRAEA THERAPEUTICS LLC | 320 LOGUE AVE | MOUNTAIN VIEW | CA | 94043 | SANTA CLARA | USA | R44DA042465 | A NOVEL APPROACH FOR PAIN TREATMENT WITHOUT OPIOID LIABILITIES | 000 | 2 | NIH | 5/6/2016 | $760,015 |
|
